NextCell Pharma AB (“NextCell”) announced earlier this week that the clinical diabetes trial ProTrans-2 had met the primary endpoints. On the occation of that, the principal investigator Professor Per-Ola Carlsson together with NextCell will hold a webcast presentation today, Thursday 10 September at 16.00.
The result from the clinical trial ProTrans-2 said that patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).
Today, on Thursday the 10th of September at 16:00, Professor Per-Ola Carlsson and the NextCell team invites you to a webcast presentation of the results and the roadmap forward for ProTrans in type-1 diabetes. The presentation will be held in English and is hosted by Nyhetsbyrån Direkt and Direkt Studios and can be watched at:
